Moreover, the 36-month beta value for RNAC is 0.47. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for RNAC is 8.55M and currently, short sellers hold a 24.58% of that float. On March 18, 2025, RNAC’s average trading volume was 94.81K shares.
RNAC) stock’s latest price update
The stock of Cartesian Therapeutics Inc (NASDAQ: RNAC) has decreased by -8.61 when compared to last closing price of 15.80. Despite this, the company has experienced a -19.37% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-06 that FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company’s common stock with an exercise price of $17.50, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as to 25% on March 3, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on March 3, 2029. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee’s entry into employment with the Company.
RNAC’s Market Performance
RNAC’s stock has fallen by -19.37% in the past week, with a monthly drop of -24.12% and a quarterly drop of -39.30%. The volatility ratio for the week is 8.66% while the volatility levels for the last 30 days are 5.82% for Cartesian Therapeutics Inc The simple moving average for the last 20 days is -19.89% for RNAC stock, with a simple moving average of -25.16% for the last 200 days.
Analysts’ Opinion of RNAC
Many brokerage firms have already submitted their reports for RNAC stocks, with BTIG Research repeating the rating for RNAC by listing it as a “Buy.” The predicted price for RNAC in the upcoming period, according to BTIG Research is $42 based on the research report published on December 19, 2024 of the previous year 2024.
RNAC Trading at -21.61% from the 50-Day Moving Average
After a stumble in the market that brought RNAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.51% of loss for the given period.
Volatility was left at 5.82%, however, over the last 30 days, the volatility rate increased by 8.66%, as shares sank -26.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.37% lower at present.
During the last 5 trading sessions, RNAC fell by -19.37%, which changed the moving average for the period of 200-days by -48.90% in comparison to the 20-day moving average, which settled at $18.02. In addition, Cartesian Therapeutics Inc saw -19.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAC starting from SPRINGER TIMOTHY A, who purchase 16,945 shares at the price of $17.35 back on Jan 13 ’25. After this action, SPRINGER TIMOTHY A now owns 8,527,440 shares of Cartesian Therapeutics Inc, valued at $293,958 using the latest closing price.
SPRINGER TIMOTHY A, the Director of Cartesian Therapeutics Inc, purchase 4,022 shares at $18.00 during a trade that took place back on Jan 14 ’25, which means that SPRINGER TIMOTHY A is holding 8,531,462 shares at $72,396 based on the most recent closing price.
Stock Fundamentals for RNAC
Current profitability levels for the company are sitting at:
- -1.13 for the present operating margin
- 0.99 for the gross margin
The net margin for Cartesian Therapeutics Inc stands at -1.99. The total capital return value is set at -0.11. Equity return is now at value -938.38, with -102.11 for asset returns.
Based on Cartesian Therapeutics Inc (RNAC), the company’s capital structure generated 1.95 points at debt to capital in total, while cash flow to debt ratio is standing at -1.69.
Currently, EBITDA for the company is -75.99 million with net debt to EBITDA at 2.61. When we switch over and look at the enterprise to sales, we see a ratio of 4.44. The receivables turnover for the company is 44.62for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.70.
Conclusion
To wrap up, the performance of Cartesian Therapeutics Inc (RNAC) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
